ArticlePakistan journal of medical sciences2026
Efficacy of Bromhexine hydrochloride combined with bronchoalveolar lavage under fiberoptic bronchoscopy in the treatment of mild to moderate community-acquired pneumonia.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy of bromhexine hydrochloride (BRH) combined with fiberoptic bronchoalveolar lavage (BAL) under fiberoptic bronchoscopy (FOB) in the treatment of patients with community-acquired pneumonia (CAP). Methodology: This retrospective cohort study included clinical data from 126 patients with mild-to-moderate CAP treated at Yongkang First People's Hospital from March 2023 to March 2025. Of them, patients treated with BRH alone (BRH group, n=63) were matched 1:1 to a cohort treated with BRH combined with fiberoptic bronchoscopic BAL under FOB (BRH & BAL group, n=63). The primary outcome was clinical efficacy. Secondary outcomes included clinical symptoms, levels of inflammatory factors, and incidence of adverse reactions. Results: After treatment, the efficacy of the BRH & BAL group (95.2%) was significantly higher than that of the BRH group (84.1%) (P<0.05). Post-treatment duration of fever, time to cough relief, time to resolution of pulmonary rales, and hospital length of stay in the BRH & BAL group were all shorter than those in the BRH group (P<0.05). After treatment, the levels of IL-6, CRP, and PCT in both groups were considerably lower than pre-treatment and significantly lower in the BRH & BAL group than in the BRH group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: BRH combined with BAL under FOB for the treatment of mild-to-moderate CAP is associated with improved therapeutic efficacy, alleviation of clinical symptoms, reduction of the inflammatory response, and good safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.